ライフサイエンスコーパス: antiphospholipid syndrome

1 mplexes (as would occur in patients with the antiphospholipid syndrome).

2 m explaining adverse obstetrical outcomes in antiphospholipid syndrome.

3 contribute to the prothrombotic diathesis in antiphospholipid syndrome.

4 criteria for diagnosis and treatment of the antiphospholipid syndrome.

5 ctively bound IgG derived from patients with antiphospholipid syndrome.

6 systemic lupus erythematosus or catastrophic antiphospholipid syndrome.

7 re particularly relevant to Ags important in antiphospholipid syndrome.

8 ipid antibodies present in patients with the antiphospholipid syndrome.

9 ologic findings in patients with established antiphospholipid syndrome.

10 osclerosis in autoimmune disease such as the antiphospholipid syndrome.

11 excluded patients with malignant disease and antiphospholipid syndrome.

12 ogenic aPL may be generated in patients with antiphospholipid syndrome.

13 eye is involved frequently in patients with antiphospholipid syndrome.

14 anticoagulant, or a history compatible with antiphospholipid syndrome.

15 , they are useful laboratory markers for the antiphospholipid syndrome.

16 1,633 patients with positive test results of antiphospholipid syndrome.

17 seemed to complicate a diagnosis of primary antiphospholipid syndrome.

18 had serological but no clinical evidence of antiphospholipid syndrome.

19 or ACAs, may also exist in patients with the antiphospholipid syndrome.

20 Splinter hemorrhages can be a feature of the antiphospholipid syndrome.

21 s that together have been referred to as the antiphospholipid syndrome.

22 or thrombosis or other manifestations of the antiphospholipid syndrome.

23 sy specimens from patients with catastrophic antiphospholipid syndrome.

24 specimens from persons who had catastrophic antiphospholipid syndrome.

25 ndard anticoagulant treatment for thrombotic antiphospholipid syndrome.

26 in the vascular lesions associated with the antiphospholipid syndrome.

27 mus in kidney-transplant recipients with the antiphospholipid syndrome.

28 ose with systemic lupus erythematosus and/or antiphospholipid syndrome.

29 nt state in these diseases as well as in the antiphospholipid syndrome.

30 nia, thrombotic thrombocytopenia purpura and antiphospholipid syndrome.

31 dies promote atherosclerosis in persons with antiphospholipid syndrome.

32 a and beta(2)-glycoprotein-I (beta(2)GPI) in antiphospholipid syndrome.

33 new targets for therapeutic intervention in antiphospholipid syndrome.

34 ity of autoantibodies found in patients with antiphospholipid syndrome.

35 for therapy to prevent pregnancy loss in the antiphospholipid syndrome.

36 cted at a French referral center for SLE and antiphospholipid syndrome, 24 patients with SLE, with a

37 A high percentage of patients with antiphospholipid syndrome (41%) and systemic lupus eryth

38 sed by LV thrombus (63% vs. 13%, p < 0.001), antiphospholipid syndrome (73% vs. 13%, p < 0.001), and

39 sed by LV thrombus (69% vs. 21%, p < 0.001), antiphospholipid syndrome (87% v 21%, p < 0.001), and no

40 Patients with radiologic evidence of antiphospholipid syndrome and no other hypercoagulable s

41 ective and safe alternative in patients with antiphospholipid syndrome and previous venous thromboemb

42 seases such as systemic lupus erythematosus, antiphospholipid syndrome and rheumatoid arthritis.

43 ive immune responses with innate immunity in antiphospholipid syndrome and systemic lupus erythematos

44 s, such as heparin-induced thrombocytopenia, antiphospholipid syndrome and thrombotic thrombocytopeni

45 treatment for most patients with thrombotic antiphospholipid syndrome and, based on current data, ap

46 expansions in JPH3, a fourth patient with an antiphospholipid syndrome, and a fifth patient with B12

47 nts with systemic lupus erythematosus or the antiphospholipid syndrome, and a subset of such antibodi

48 such as mechanical heart valves, thrombotic antiphospholipid syndrome, and atrial fibrillation assoc

49 autoimmune hemolytic anemia, (catastrophic) antiphospholipid syndrome, and C3 glomerulopathy are con

50 y artery disease, peripheral artery disease, antiphospholipid syndrome, and cancer.

51 rs such as heparin-induced thrombocytopenia, antiphospholipid syndrome, and therapy with asparaginase

52 scuss the first known case of a patient with antiphospholipid syndrome (APLS), ESLD complicated by he

53 y complications: a mouse model of obstetrics antiphospholipid syndrome (APS) and a mouse model of pre

54 d with thrombosis in patients diagnosed with antiphospholipid syndrome (APS) and enhance thrombus for

55 Male (NZW x BXSB)F(1) mice develop antiphospholipid syndrome (APS) and proliferative glomer

56 pid antibodies (aPL) in primary or secondary antiphospholipid syndrome (APS) are a major cause for ac

57 Patients with antiphospholipid syndrome (APS) are at a high risk of de

58 Pregnant women with antiphospholipid syndrome (APS) are at a high risk of ob

59 Using antiphospholipid syndrome (APS) as a model, we demonstra

60 iphospholipid Abs (aPL) in patients with the antiphospholipid syndrome (APS) bind to the homologous e

61 Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) can be associated with s

62 Antiphospholipid syndrome (APS) consists of thrombotic,

63 Xa reactive IgG isolated from patients with antiphospholipid syndrome (APS) display higher avidity b

64 lar weight heparin [LDA+LMWH]) for obstetric antiphospholipid syndrome (APS) does not prevent life-th

65 tscher-like retinopathy complicating primary antiphospholipid syndrome (APS) following coronary arter

66 the pathogenesis, diagnosis and treatment of antiphospholipid syndrome (APS) from current literature.

67 The classification criteria for both SLE and antiphospholipid syndrome (APS) have been updated, and u

68 Antiphospholipid syndrome (APS) is a rare autoimmune dis

69 The antiphospholipid syndrome (APS) is a systemic autoimmune

70 Antiphospholipid syndrome (APS) is a thrombo-inflammator

71 Antiphospholipid syndrome (APS) is an autoimmune disease

72 Antiphospholipid syndrome (APS) is an autoimmune disorde

73 major mechanism of hypercoagulability in the antiphospholipid syndrome (APS) is antiphospholipid Ab-m

74 The antiphospholipid syndrome (APS) is characterized by recu

75 The antiphospholipid syndrome (APS) is characterized by recu

76 Antiphospholipid syndrome (APS) is characterized by recu

77 The antiphospholipid syndrome (APS) is characterized by thro

78 Antiphospholipid syndrome (APS) is defined by recurrent

79 The antiphospholipid syndrome (APS) is defined by the persis

80 The antiphospholipid syndrome (APS) is defined by thrombosis

81 Antiphospholipid syndrome (APS) is defined by thrombosis

82 The standard treatment of thrombotic antiphospholipid syndrome (APS) is lifelong oral anticoa

83 Antiphospholipid syndrome (APS) is well recognized as an

84 r pregnancy loss and either purely obstetric antiphospholipid syndrome (APS) or inherited thrombophil

85 olipid antibodies (aPL) in patients with the antiphospholipid syndrome (APS) recognize a conformation

86 e prothrombotic or proinflammatory status of antiphospholipid syndrome (APS) remain unknown.

87 ibodies test can identify some patients with antiphospholipid syndrome (APS) that are negative for ot

88 for women with the purely obstetric form of antiphospholipid syndrome (APS) treated with prophylacti

89 mmunoglobulin G (IgG) from patients with the antiphospholipid syndrome (APS) upon monocyte activation

90 Women with antiphospholipid syndrome (APS), a condition characteriz

91 get of antiphospholipid antibodies (aPLs) in antiphospholipid syndrome (APS), a life-threatening auto

92 In the antiphospholipid syndrome (APS), antiphospholipid Abs (a

93 In antiphospholipid syndrome (APS), antiphospholipid antibo

94 -glycoprotein I (beta2GPI) are a hallmark of antiphospholipid syndrome (APS), associated with an incr

95 e clinical phenotype, including catastrophic antiphospholipid syndrome (APS), atypical presentations

96 ome (CAPS) is a severe, rare complication of antiphospholipid syndrome (APS), but cutaneous involveme

97 linked to autoimmune disorders, particularly antiphospholipid syndrome (APS), in which autoantibodies

98 re COVID-19 and resemble hypercoagulation of antiphospholipid syndrome (APS), our approach focused on

99 sis and thrombocytopenia are features of the antiphospholipid syndrome (APS), suggesting that antipho

100 ion and vascular thrombosis in patients with antiphospholipid syndrome (APS).

101 y with antiphospholipid antibodies is termed antiphospholipid syndrome (APS).

102 to promote thrombosis and fetal loss in the antiphospholipid syndrome (APS).

103 IgG anti-tPA antibodies in patients with the antiphospholipid syndrome (APS).

104 ) is the most common disease associated with antiphospholipid syndrome (APS).

105 ctly contribute to hypercoagulability in the antiphospholipid syndrome (APS).

106 Ab (aPL) and thrombosis is recognized as the antiphospholipid syndrome (APS).

107 )GPI) appear to be a critical feature of the antiphospholipid syndrome (APS).

108 b (aCL), and thrombosis is recognized as the antiphospholipid syndrome (APS).

109 manifestations is now well-recognized as the antiphospholipid syndrome (APS).

110 with systemic lupus erythematosus or primary antiphospholipid syndrome (APS).

111 (designated IS6) from a patient with primary antiphospholipid syndrome (APS).

112 th recurrent thrombosis in patients with the antiphospholipid syndrome (APS).

113 thrombosis are frequent complications of the antiphospholipid syndrome (APS).

114 the major antigen in the autoimmune disorder antiphospholipid syndrome (APS).

115 s) effect thrombotic events in patients with antiphospholipid syndrome (APS).

116 ss grafting in a female patient with primary antiphospholipid syndrome (APS).

117 (aPL) in the acquired coagulopathy known as antiphospholipid syndrome (APS).

118 omboinflammatory autoimmune disease known as antiphospholipid syndrome (APS).

119 ystemic cause and was diagnosed with primary antiphospholipid syndrome (APS).

120 the effect of antibodies from patients with antiphospholipid syndrome (APS).

121 patients with non-criteria manifestations of antiphospholipid syndrome (APS).

122 ribute to thrombosis and miscarriages in the antiphospholipid syndrome (APS).

123 e the mid-1980s for diagnosing patients with antiphospholipid syndrome (APS).

124 s positively correlated with the symptoms of antiphospholipid syndromes (APS), including thrombosis a

125 ere treated with IgG aPL (from patients with antiphospholipid syndrome [APS]) or with control IgG (fr

126 otic mechanisms, women with purely obstetric antiphospholipid syndrome are at risk for thrombotic com

127 ations of this findings in patients with the antiphospholipid syndrome are discussed.

128 at cause anticoagulant-refractory thrombotic antiphospholipid syndrome are now better understood.

129 pathways involved in the vasculopathy of the antiphospholipid syndrome are unknown, and adequate ther

130 ts with systemic lupus erythematosus and the antiphospholipid syndrome, are associated with adverse p

131 lar risks, lupus nephritis, CNS disease, the antiphospholipid syndrome, assessment of disease activit

132 roquine and the statins for the treatment of antiphospholipid syndrome-associated clinical manifestat

133 ay hold promise as a therapeutic approach to antiphospholipid syndrome-associated pregnancy complicat

134 ndrome patient sera are not only a marker of antiphospholipid syndrome but are directly involved in t

135 Anticoagulant-refractory thrombotic antiphospholipid syndrome can be broadly defined as brea

136 Catastrophic antiphospholipid syndrome (CAPS) is a potentially lethal

137 Catastrophic antiphospholipid syndrome (CAPS) is a severe, rare compl

138 Catastrophic antiphospholipid syndrome (CAPS) is characterized by his

139 The catastrophic antiphospholipid syndrome (CAPS) is rare and usually fat

140 is is considered the cardinal feature of the antiphospholipid syndrome, chronic vascular lesions are

141 dies purified from the sera of patients with antiphospholipid syndrome complicated by thrombosis grea

142 NT FINDINGS: Although the pathophysiology of antiphospholipid syndrome continues to be poorly underst

143 Many patients with antiphospholipid syndrome had decreased ectonucleotidase

144 the antibodies and antigens involved in the antiphospholipid syndrome has provided many new insights

145 lycoprotein I (beta2GPI) cause thrombosis in antiphospholipid syndrome; however, the role of beta2GPI

146 me that involves the injection of high-titer antiphospholipid syndrome human serum, complement activa

147 munoglobulin G (IgG) from a patient with the antiphospholipid syndrome (IgG-APS) and then fed with hy

148 e either purified IgG from patients with the antiphospholipid syndrome (IgG-APS) or normal IgG from h

149 G (IgG) isolated from either a patient with antiphospholipid syndrome (IgG-APS), a healthy control s

150 primarily on the spectrum and management of antiphospholipid syndrome in children; this review summa

151 hile the 956A allele was associated with the antiphospholipid syndrome in patients with SLE (P = 0.00

152 s in the glomeruli, recapitulating the human antiphospholipid syndrome in these mice.

153 Vascular complications of antiphospholipid syndrome include serious and life-threa

154 controversial issues in the treatment of the antiphospholipid syndrome include the use of less intens

155 Antiphospholipid syndrome includes elevation of either t

156 The antiphospholipid syndrome is a disorder of recurrent thr

157 The antiphospholipid syndrome is a major feature of systemic

158 PURPOSE OF REVIEW: Antiphospholipid syndrome is a rare cause of ocular vaso

159 The antiphospholipid syndrome is a thrombophilic condition m

160 Antiphospholipid syndrome is an autoimmune disease chara

161 with lupus, the stand alone presentation of antiphospholipid syndrome is at least equally common.

162 Antiphospholipid syndrome is characterized by recurrent

163 The antiphospholipid syndrome is characterized by thrombosis

164 Antiphospholipid syndrome is characterized by thrombosis

165 Antiphospholipid syndrome is characterized by thrombosis

166 The antiphospholipid syndrome is characterized clinically by

167 Diagnosis and treatment of antiphospholipid syndrome is difficult, however, because

168 m, but whether it is useful in patients with antiphospholipid syndrome is uncertain.

169 f thrombosis in the purely obstetric form of antiphospholipid syndrome is uncertain.

170 l events were identified: 1 case of maternal antiphospholipid syndrome leading to spontaneous abortio

171 ct (MAb 519) and from a patient with primary antiphospholipid syndrome (MAb 516).

172 ntial role of immunomodulatory treatments in antiphospholipid syndrome management is receiving increa

173 ate clinical manifestations in patients with antiphospholipid syndrome may be established.

174 f the thrombin-reactive aCL in patients with antiphospholipid syndrome may bind to PC and APC.

175 n (n = 3), and celiac occlusion secondary to antiphospholipid syndrome (n = 1).

176 rating intrarenal vessels from patients with antiphospholipid syndrome nephropathy showed indications

177 Patients with antiphospholipid syndrome nephropathy who required trans

178 essels of patients with primary or secondary antiphospholipid syndrome nephropathy.

179 by The Nimes Obstetricians and Hematologists-Antiphospholipid Syndrome (NOH-APS) Study Group give us

180 related to systemic lupus erythematosus and antiphospholipid syndrome occur in association with mult

181 evated liver enzymes low platelets syndrome; antiphospholipid syndrome); or, ultimately, to diagnose

182 s such as those with severe renal failure or antiphospholipid syndrome, or cancer, respectively.

183 a (HIT), beta-2-glycoprotein-1 implicated in antiphospholipid syndrome, or red blood cells coated wit

184 re COVID-19 and resemble hypercoagulation of antiphospholipid syndrome, our approach focused on antip

185 Primary antiphospholipid syndrome (PAPS) is a life-threatening c

186 ic lupus erythematosus (SLE) but not primary antiphospholipid syndrome (PAPS), a nonlupus systemic au

187 Studies of antiphospholipid syndrome pathogenesis have long focused

188 that anti-beta(2)-GP1 IgG autoantibodies in antiphospholipid syndrome patient sera are not only a ma

189 anti-cardiolipin mAbs derived from a primary antiphospholipid syndrome patient.

190 anticoagulation are similarly protective in antiphospholipid syndrome patients after the first throm

191 Catastrophic antiphospholipid syndrome patients usually receive a com

192 r subsets of antiphospholipid Abs present in antiphospholipid syndrome patients.

193 t rejection, major trauma, severe burns, the antiphospholipid syndrome, preeclampsia, sickle cell dis

194 stemic lupus erythematosus (SLE) and primary antiphospholipid syndrome (primary APS) undergoing OI/IV

195 Patients with thrombotic antiphospholipid syndrome randomized to DOACs compared w

196 rs, such as rheumatoid arthritis and primary antiphospholipid syndrome, reacted infrequently.

197 gulants (DOACs) for patients with thrombotic antiphospholipid syndrome remain controversial.

198 es (such as systemic lupus erythematosus and antiphospholipid syndrome) representing the two ends of

199 Pregnancy complicated by antiphospholipid syndrome requires expert care and a tea

200 toantigens/clones, i.e ., lupus nephritis or antiphospholipid syndrome should benefit from combinatio

201 ative colitis, systemic lupus erythematosus, antiphospholipid syndrome, Sjogren syndrome, myasthenia

202 cells, IgG antibodies from patients with the antiphospholipid syndrome stimulated mTORC through the p

203 In the mouse model of antiphospholipid syndrome that involves the injection of

204 th the spectrum of clinical manifestation of antiphospholipid syndrome, the diagnostic criteria of th

205 k for developing thrombosis in patients with antiphospholipid syndrome, the majority of pathogenic aP

206 n documented as a biomarker for diagnosis of antiphospholipid syndrome, their direct role in the path

207 of the immunology and pathophysiology of the antiphospholipid syndrome, treating this condition remai

208 f polyclonal IgG purified from patients with antiphospholipid syndrome, using both solid-phase and fl

209 Although antiphospholipid syndrome was first recognized in patien

210 Catastrophic antiphospholipid syndrome was the first APS manifestatio

211 a(2)-GP1 autoantibodies from 3 patients with antiphospholipid syndrome were affinity-purified using h

212 in two UK hospitals, included patients with antiphospholipid syndrome who were taking warfarin for p